sdAbs Related Knowledge

The unique feature gives single domain antibodies asmaller size and increased stability, making them usefulfor a wide range of applications. Unlock the full potentialof single domain antibody with NBbiolab state-of-the-artsdAb discovery platform.

Nov.04,2026

How Antigen Format Influences Camelid Immune Response

How Antigen Format Influences Camelid Immune Response depends on size, valency, conformation, adjuvant compatibility, and delivery. This 阿帕克 guide provides a step-by-step framework for improving Camelid Animal Immunization and VHH discovery outcomes.

Nov.04,2026

How Antigen Format Affects Yeast Display Screening Results

How Antigen Format Affects Yeast Display Screening Results depends on folding, valency, immobilization, and accessibility. This guide shows how 阿帕克’s Yeast Display VHH Screening Service can improve hit quality and reduce false positives.

Nov.03,2026

How Library Size Affects Phage Display Nanobody Discovery

This guide explains how library size affects phage display nanobody discovery, why unique VHH diversity matters more than transformant counts, and how to plan screening, sequencing, validation, and service decisions.

Nov.03,2026

What Library Diversity Is Needed for Reliable VHH Screening

A Custom Nanobody Discovery Platform helps researchers identify stable VHH binders through library design, phage or yeast screening, sequence analysis, and functional validation.

Nov.02,2026

How to Validate Hits from Premade Nanobody Libraries

This guide explains How to Validate Hits from Premade Nanobody Libraries using a practical workflow covering sequence recovery, recombinant expression, SPR or BLI kinetics, specificity, stability, and functional confirmation with 阿帕克.

Nov.02,2026

How Expression Host Affects Nanobody Folding and Stability

This guide explains how expression hosts affect nanobody folding and stability, compares bacterial, yeast, and mammalian systems, and provides tools, testing steps, purchasing criteria, and common mistakes to avoid.

Oct.30,2026

How to Reduce On-Target Off-Tumor Binding Risk in CAR-T

This guide explains how to reduce on-target off-tumor binding risk in CAR-T through target selection, CAR-T Target Nanobody Discovery, epitope engineering, normal tissue testing, functional validation, and vendor evaluation.

Oct.29,2026

Whole Cells vs Purified Proteins for Membrane Target Screening

Whole Cells vs Purified Proteins for Membrane Target Screening explains when to use each format, how to control assay quality, and how Membrane Target Nanobody Screening can improve discovery decisions.

Oct.28,2026

How to Monitor VHH Titers During Camelid Immunization

This guide explains camelid antibody titer monitoring from preimmune sampling to serum ELISA, endpoint-titer interpretation, immunization decisions, and VHH library preparation while separating antibody quantity from affinity.

1 2